February 20, 2015
Impax Laboratories Inc. has reached an $8 million settlement with a class of shareholders who allege that the company downplayed U.S. Food and Drug Administration concerns over quality control at a California plant, it was announced Friday.
July 29, 2014
Impax Laboratories Inc. on Tuesday disclosed the U.S. Food and Drug Administration's objections to extensive quality lapses at a Taiwan manufacturing plant for its proposed Parkinson's disease medication Rytary, adding to previous production woes that have fueled investor lawsuits over lengthy delays of the drug.
April 09, 2013
Impax Laboratories Inc. was hit with a proposed class action in California federal court Monday, accusing it of misleading investors about poor conditions at one of its manufacturing plants, delaying approval for two proposed drugs and causing its stock to trade at inflated prices.